Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma.
- ProName: Sorafenib
- CasNo: 284461-73-0
- Molecular Formula: C28H24ClF3N4O6S
- Appearance: White powder
- Application: Metabolism Drug; Carcino-Chemotherapeu...
- DeliveryTime: one week
- PackAge: 25kg/drum
- Port: Shanghai
- ProductionCapacity: 200 Metric Ton/Year
- Purity: 99%min
- Storage: Store in cool & dry place.Keep away fr...
- Transportation: BY AIR,SEA
- LimitNum: 1 Kilogram
No comments:
Post a Comment